Chronic Limb-Threatening Ischemia (CLTI)

LimFlow Completes Enrollment in PROMISE II U.S. Pivotal Trial of Breakthrough Device Designed to Prevent Amputations in No-Option Patients With Chronic Limb-Threatening Ischemia

Retrieved on: 
Tuesday, March 15, 2022
Biotechnology, Surgery, Medical Devices, Health, Clinical Trials, Harvard Medical School, Â, MBA, Quality of life, Mortality, Angioplasty, Technology, Face, Vein, Method, FACS, Death, Patient, Perfusion, Hospital, Coronary artery disease, FDA, Obesity, Massachusetts General Hospital, Leg, Amputation, Infection, Diabetes, Professor, Assistant, Diamond clarity, Ageing, Surgery, CE marking, Sale, Degenerative disease, Kidney disease, Wound healing, Prevalence, Foot, Incidence, Population, PAD, Chronic pain, Artery, Peripheral artery disease, Department, MS, Chronic limb threatening ischemia, Disease, Pharmaceutical industry, Medical imaging, MD, Chronic Limb-Threatening Ischemia (CLTI), LimFlow and the LimFlow System, CHRONIC LIMB-THREATENING ISCHEMIA (CLTI), LIMFLOW AND THE LIMFLOW SYSTEM

The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.

Key Points: 
  • The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.
  • The no-option patients treated in PROMISE II were determined by an independent physician committee to be no longer eligible for conventional endovascular or surgical therapy to treat CLTI.
  • The PROMISE II investigators are very encouraged by our experience using the LimFlow System to treat CLTI patients with no other options.
  • LimFlow also announced completion of enrollment in the CLariTI study of approximately 200 high-risk and no-option CLTI patients.